Reuters logo
BRIEF-Neurocrine provides update on FDA advisory committee for ingrezza for treatment of Tardive Dyskinesia
January 5, 2017 / 9:35 PM / 10 months ago

BRIEF-Neurocrine provides update on FDA advisory committee for ingrezza for treatment of Tardive Dyskinesia

Jan 5 (Reuters) - Neurocrine Biosciences Inc :

* Neurocrine provides update on FDA advisory committee for ingrezza (valbenazine) for the treatment of tardive dyskinesia

* Neurocrine biosciences - fda informed co that priority review of nda of ingrezza is continuing as planned with previously announced pdufa date of april 11, 2017

* Neurocrine biosciences -fda after further review of ingrezza nda decided to cancel psychopharmacologic drugs advisory committee meeting originally scheduled for febr 16, 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below